Latest Salix Pharmaceuticals (SLXP) Headlines R
Post# of 37
Posted On: 03/13/2014 2:02:01 PM
Latest Salix Pharmaceuticals (SLXP) Headlines
Roche Collaborates with Bayer - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 12, 4:05PM CDT
Roche's Ventana Medical Systems, Inc. has entered into a multi-year agreement with Bayer Pharma AG, thereby extending an existing collaboration between the two companies.
Can Ohr Pharmaceutical (OHRP) Continue to Surge? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Mar 12, 7:52AM CDT
Ohr Pharmaceutical has seen its Zacks Rank surge over the past four weeks, moving from Sell territory to its current position as a Buy
Salix Pharmaceuticals Up 54.7% Since SmarTrend Uptrend Call (SLXP)
Comtex SmarTrend(R) - Tue Mar 11, 5:21PM CDT
SmarTrend identified an Uptrend for Salix Pharmaceuticals (NASDAQ:SLXP) on October 2nd, 2013 at $72.19. In approximately 5 months, Salix Pharmaceuticals has returned 54.74% as of today's recent price of $111.71.
New Diagnostic Test From Roche - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 11, 10:30AM CDT
Roche recently announced that its new diagnostic test, Elecsys Syphilis immunoassay, is now available in the markets.
ArQule's Loss Narrows in Q4 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 06, 12:37PM CST
ArQule reported a loss of 10 cents per share in the fourth quarter of 2013, narrower than the Zacks Consensus Estimate of a loss of 13 cents per share.
Favorable Court Judgments, Stock Price Updates, and Upcoming Investors Conferences - Analyst Notes on Salix, Cerner, Hologic, Covance, and Synta
PR Newswire - Thu Mar 06, 8:20AM CST
Today, Analysts Review released its analysts' notes regarding Salix Pharmaceuticals Ltd. (NASDAQ: SLXP), Cerner Corporation (NASDAQ: CENR), Hologic Inc. (NASDAQ: HOLX), Covance Inc. (NYSE: CVD), and Synta Pharmaceuticals Corp. (NASDAQ: SNTA). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Top Mutual Funds Add To Health Care, Leisure And Banks
at Investor's Business Daily - Tue Mar 04, 5:20PM CST
After a volatile start in January, the stock market bounced back nicely in February with a good pop, helping to lift stock funds' recent purchases. The S&P 500 and the Dow each tacked on 4% during the Valentine month, while the biotech-heavy Nasdaq...
Salix Pharmaceuticals Shares Up 53.1% Since SmarTrend's Buy Recommendation (SLXP)
Comtex SmarTrend(R) - Tue Mar 04, 11:09AM CST
SmarTrend identified an Uptrend for Salix Pharmaceuticals (NASDAQ:SLXP) on October 2nd, 2013 at $72.19. In approximately 5 months, Salix Pharmaceuticals has returned 53.07% as of today's recent price of $110.50.
Salix Pharmaceuticals to Present at ROTH Conference
Business Wire - Tue Mar 04, 6:00AM CST
Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that the Company will present at the 26th Annual ROTH Conference in Laguna Niguel, CA on Tuesday, March 11, 2014 at 1:30 p.m. PT (4:30 p.m. ET).
2 Weak Breakouts, A Few Sell-Offs For The IBD 50
at Investor's Business Daily - Fri Feb 28, 5:25PM CST
A couple of IBD 50 stocks broke out Friday, as the list of top-performing stocks also suffered at the hands of a few components that tumbled badly. The breakouts belonged to Signature Bank (SBNY) and Chipotle Mexican Grill (CMG). Chipotle saw a...
Stocks Hold Near Fresh Highs; 58.com Surges
at Investor's Business Daily - Fri Feb 28, 11:04AM CST
Stocks were holding near their session highs near Friday's midpoint. Overall, equities rallied in spite of a round of mixed economic data, including a downward revision to economic growth. The S&P 500 and the Nasdaq were up 0.5% and 0.2%,...
Stocks Buck Up In Early Trade; Salix, MercadoLibre On Fire
at Investor's Business Daily - Fri Feb 28, 9:37AM CST
Stocks pulled up from narrow early losses Friday after Midwest manufacturing and February consumer sentiment numbers topped expectations. All three major indexes, the Nasdaq, S&P 500 and the Dow Jones industrial average, were up 0.5% in early trade....
After Yesterday's Rally of 1.44% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Thu Feb 27, 5:38PM CST
Salix Pharmaceuticals (NASDAQ:SLXP) traded in a range yesterday that spanned from a low of $108.14 to a high of $111.26. Yesterday, the shares gained 1.4%, which took the trading range above the 3-day high of $110.93 on volume of 865,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Stocks End Higher; MercadoLibre Jumps After Hours
at Investor's Business Daily - Thu Feb 27, 3:58PM CST
Major averages closed higher Thursday after Federal Reserve chair Janet Yellen said bad weather may be behind recent weak economic data. The Nasdaq climbed 0.6%, while the Dow Jones industrial average and the S&P 500 added 0.5% each. But volume was...
Salix Pharmaceuticals Reports 4Q2013 and FY2013 Results
Business Wire - Thu Feb 27, 3:01PM CST
-- Full Year Product Revenue Increases 27% to $934 million
RedHill Biopharma and Salix Pharmaceuticals Announce Worldwide Exclusive License Agreement for RedHill's RHB-106 Encapsulated Bowel Preparation
GlobeNewswire - Thu Feb 27, 8:53AM CST
Salix Pharmaceuticals Ltd. (Nasdaq:SLXP) and RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) today announced that they have entered into an exclusive agreement by which Salix has licensed the worldwide exclusive rights to RedHill's RHB-106 encapsulated formulation for bowel preparation and rights to other purgative developments.
Salix Pharmaceuticals and RedHill Biopharma Announce Worldwide Exclusive License Agreement for RedHill's RHB-106 Encapsulated Bowel Preparation
Business Wire - Thu Feb 27, 6:43AM CST
Salix Pharmaceuticals Ltd. (NASDAQ: SLXP) and RedHill Biopharma Ltd. (NASDAQ: RDHL; TASE: RDHL) today announced that they have entered into an exclusive agreement by which Salix has licensed the worldwide exclusive rights to RedHill's RHB-106 encapsulated formulation for bowel preparation and rights to other purgative developments.
Salix Wins Napo Pharmaceuticals Litigation
Business Wire - Tue Feb 25, 12:29PM CST
--Jury Finds Salix Did Not Breach License Agreement
Salix Pharmaceuticals Has Returned 49.5% Since SmarTrend Recommendation (SLXP)
Comtex SmarTrend(R) - Tue Feb 25, 10:03AM CST
SmarTrend identified an Uptrend for Salix Pharmaceuticals (NASDAQ:SLXP) on October 2nd, 2013 at $72.19. In approximately 5 months, Salix Pharmaceuticals has returned 49.54% as of today's recent price of $107.95.
Digia announces major update to Qt Enterprise Embedded out-of-the-box embedded software development offering
Business Wire - Tue Feb 25, 3:55AM CST
Embedded World -- Digia has released a major update to Qt Enterprise Embedded, the fully-integrated solution that enables users to get started immediately with software development for an embedded device with a tailored user experience. The Qt Enterprise Embedded update introduces several new value-add features that further increase developer efficiency, application and device performance and ultimately shortens software embedded development time to just hours.
Roche Collaborates with Bayer - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 12, 4:05PM CDT
Roche's Ventana Medical Systems, Inc. has entered into a multi-year agreement with Bayer Pharma AG, thereby extending an existing collaboration between the two companies.
Can Ohr Pharmaceutical (OHRP) Continue to Surge? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Mar 12, 7:52AM CDT
Ohr Pharmaceutical has seen its Zacks Rank surge over the past four weeks, moving from Sell territory to its current position as a Buy
Salix Pharmaceuticals Up 54.7% Since SmarTrend Uptrend Call (SLXP)
Comtex SmarTrend(R) - Tue Mar 11, 5:21PM CDT
SmarTrend identified an Uptrend for Salix Pharmaceuticals (NASDAQ:SLXP) on October 2nd, 2013 at $72.19. In approximately 5 months, Salix Pharmaceuticals has returned 54.74% as of today's recent price of $111.71.
New Diagnostic Test From Roche - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 11, 10:30AM CDT
Roche recently announced that its new diagnostic test, Elecsys Syphilis immunoassay, is now available in the markets.
ArQule's Loss Narrows in Q4 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 06, 12:37PM CST
ArQule reported a loss of 10 cents per share in the fourth quarter of 2013, narrower than the Zacks Consensus Estimate of a loss of 13 cents per share.
Favorable Court Judgments, Stock Price Updates, and Upcoming Investors Conferences - Analyst Notes on Salix, Cerner, Hologic, Covance, and Synta
PR Newswire - Thu Mar 06, 8:20AM CST
Today, Analysts Review released its analysts' notes regarding Salix Pharmaceuticals Ltd. (NASDAQ: SLXP), Cerner Corporation (NASDAQ: CENR), Hologic Inc. (NASDAQ: HOLX), Covance Inc. (NYSE: CVD), and Synta Pharmaceuticals Corp. (NASDAQ: SNTA). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Top Mutual Funds Add To Health Care, Leisure And Banks
at Investor's Business Daily - Tue Mar 04, 5:20PM CST
After a volatile start in January, the stock market bounced back nicely in February with a good pop, helping to lift stock funds' recent purchases. The S&P 500 and the Dow each tacked on 4% during the Valentine month, while the biotech-heavy Nasdaq...
Salix Pharmaceuticals Shares Up 53.1% Since SmarTrend's Buy Recommendation (SLXP)
Comtex SmarTrend(R) - Tue Mar 04, 11:09AM CST
SmarTrend identified an Uptrend for Salix Pharmaceuticals (NASDAQ:SLXP) on October 2nd, 2013 at $72.19. In approximately 5 months, Salix Pharmaceuticals has returned 53.07% as of today's recent price of $110.50.
Salix Pharmaceuticals to Present at ROTH Conference
Business Wire - Tue Mar 04, 6:00AM CST
Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that the Company will present at the 26th Annual ROTH Conference in Laguna Niguel, CA on Tuesday, March 11, 2014 at 1:30 p.m. PT (4:30 p.m. ET).
2 Weak Breakouts, A Few Sell-Offs For The IBD 50
at Investor's Business Daily - Fri Feb 28, 5:25PM CST
A couple of IBD 50 stocks broke out Friday, as the list of top-performing stocks also suffered at the hands of a few components that tumbled badly. The breakouts belonged to Signature Bank (SBNY) and Chipotle Mexican Grill (CMG). Chipotle saw a...
Stocks Hold Near Fresh Highs; 58.com Surges
at Investor's Business Daily - Fri Feb 28, 11:04AM CST
Stocks were holding near their session highs near Friday's midpoint. Overall, equities rallied in spite of a round of mixed economic data, including a downward revision to economic growth. The S&P 500 and the Nasdaq were up 0.5% and 0.2%,...
Stocks Buck Up In Early Trade; Salix, MercadoLibre On Fire
at Investor's Business Daily - Fri Feb 28, 9:37AM CST
Stocks pulled up from narrow early losses Friday after Midwest manufacturing and February consumer sentiment numbers topped expectations. All three major indexes, the Nasdaq, S&P 500 and the Dow Jones industrial average, were up 0.5% in early trade....
After Yesterday's Rally of 1.44% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Thu Feb 27, 5:38PM CST
Salix Pharmaceuticals (NASDAQ:SLXP) traded in a range yesterday that spanned from a low of $108.14 to a high of $111.26. Yesterday, the shares gained 1.4%, which took the trading range above the 3-day high of $110.93 on volume of 865,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Stocks End Higher; MercadoLibre Jumps After Hours
at Investor's Business Daily - Thu Feb 27, 3:58PM CST
Major averages closed higher Thursday after Federal Reserve chair Janet Yellen said bad weather may be behind recent weak economic data. The Nasdaq climbed 0.6%, while the Dow Jones industrial average and the S&P 500 added 0.5% each. But volume was...
Salix Pharmaceuticals Reports 4Q2013 and FY2013 Results
Business Wire - Thu Feb 27, 3:01PM CST
-- Full Year Product Revenue Increases 27% to $934 million
RedHill Biopharma and Salix Pharmaceuticals Announce Worldwide Exclusive License Agreement for RedHill's RHB-106 Encapsulated Bowel Preparation
GlobeNewswire - Thu Feb 27, 8:53AM CST
Salix Pharmaceuticals Ltd. (Nasdaq:SLXP) and RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) today announced that they have entered into an exclusive agreement by which Salix has licensed the worldwide exclusive rights to RedHill's RHB-106 encapsulated formulation for bowel preparation and rights to other purgative developments.
Salix Pharmaceuticals and RedHill Biopharma Announce Worldwide Exclusive License Agreement for RedHill's RHB-106 Encapsulated Bowel Preparation
Business Wire - Thu Feb 27, 6:43AM CST
Salix Pharmaceuticals Ltd. (NASDAQ: SLXP) and RedHill Biopharma Ltd. (NASDAQ: RDHL; TASE: RDHL) today announced that they have entered into an exclusive agreement by which Salix has licensed the worldwide exclusive rights to RedHill's RHB-106 encapsulated formulation for bowel preparation and rights to other purgative developments.
Salix Wins Napo Pharmaceuticals Litigation
Business Wire - Tue Feb 25, 12:29PM CST
--Jury Finds Salix Did Not Breach License Agreement
Salix Pharmaceuticals Has Returned 49.5% Since SmarTrend Recommendation (SLXP)
Comtex SmarTrend(R) - Tue Feb 25, 10:03AM CST
SmarTrend identified an Uptrend for Salix Pharmaceuticals (NASDAQ:SLXP) on October 2nd, 2013 at $72.19. In approximately 5 months, Salix Pharmaceuticals has returned 49.54% as of today's recent price of $107.95.
Digia announces major update to Qt Enterprise Embedded out-of-the-box embedded software development offering
Business Wire - Tue Feb 25, 3:55AM CST
Embedded World -- Digia has released a major update to Qt Enterprise Embedded, the fully-integrated solution that enables users to get started immediately with software development for an embedded device with a tailored user experience. The Qt Enterprise Embedded update introduces several new value-add features that further increase developer efficiency, application and device performance and ultimately shortens software embedded development time to just hours.
(0)
(0)Salix Pharmaceuticals Ltd. (SLXP) Stock Research Links
Scroll down for more posts ▼